Magazine Article | January 9, 2018

One Small Startup's Quest For Funding Gets Creative

Source: Life Science Leader

By Camille Mojica Rey, Contributing Writer
Follow Me On Twitter @CamilleReyATX

It’s no wonder small biopharma companies are acquired by their larger counterparts only after clinical trials show a novel drug’s potential for success. R&D costs are expensive, accounting for about half of the average cost to develop and gain marketing approval for a new drug. That leaves those small startups with the job of raising massive amounts of money just to stay afloat during the clinical trials process — and hoping for an acquisition exit.

As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company. “Every small biotech understands that it costs so much and takes so much infrastructure to commercialize your own product that M&A is inevitably at the top of the list of options for getting a product to market,” she says. “Seeking funding is a 24/7 job. As soon as we get money, I’m out looking for more.”

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: